Lv4
546 积分 2025-11-12 加入
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
28天前
已完结
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
1个月前
已完结
The Harvard-Emory ECG Database
2个月前
已关闭
“Biological R2” resection for intrahepatic cholangiocarcinoma: identification of patients at risk for poor oncologic outcomes after curative-intent resection
2个月前
已关闭
Nomogram for prediction of severe postoperative complications in elective hepato-pancreato-biliary surgery after COVID-19 breakthrough infection: A large multicenter study
2个月前
已关闭
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial
2个月前
已完结
"Biological R2" resection for intrahepatic cholangiocarcinoma: identification of patients at risk for poor oncologic outcomes after curative-intent resection
2个月前
已完结
International validation of a natural-killer-cell–based model to predict recurrence-free survival in hepatocellular carcinoma
2个月前
已关闭
Beyond the composite: Differential impact of albumin and bilirubin relative to tumor burden in HCC
2个月前
已关闭
Beyond the composite: Differential impact of albumin and bilirubin relative to tumor burden in HCC
2个月前
已关闭
皖公网安备34019202002308
